What did @justagrownwoman actually say?
The creator told her audience that LL37 is "one of the big headways in the Lyme disease community" and can "kill the bacteria" in lab settings. She acknowledged the lack of human studies, called it "research only," and warned viewers they'd be their "own guinea pig." Then, in what she framed as leaving dosing info unsaid, she implied people should simply go find it online. That last move is the part worth scrutinizing closely.
To her credit, she was upfront that human data is thin and that the bacteria can hide in tissue in ways that complicate delivery. She did not claim it was a cure. But enthusiastically suggesting viewers go source an unregulated injectable peptide for a complex chronic illness, while gesturing at dosing without saying it out loud, is not a responsible middle ground. It is a liability dodge dressed up as restraint.
Does the science back this up?
The lab evidence for LL37 against Borrelia burgdorferi is real but early. It does not justify self-injection from an unverified online source.
LL37 is a human cathelicidin antimicrobial peptide, naturally produced by neutrophils, epithelial cells, and macrophages. In vitro studies have shown it can disrupt bacterial membranes, including those of Borrelia. A 2019 paper by Guerau-de-Arellano and colleagues in Frontiers in Immunology outlined cathelicidin activity against spirochetes and noted that LL37 demonstrated direct antimicrobial effects under controlled lab conditions. That part checks out.
What the creator glosses over: in vitro results and human pharmacokinetics are entirely different problems. LL37 has a short half-life, is subject to rapid proteolytic degradation in vivo, and has shown cytotoxic effects at higher concentrations in cell studies. There are no completed Phase II or Phase III randomized controlled trials in Lyme disease as of this writing. The creator says "good luck" finding a clinical trial, which is actually the correct advice, but not in the cheerful tone she used.
What did they get wrong (or right)?
She got the basic antimicrobial premise right. She got almost everything practical wrong.
First, characterizing LL37 as a "big headway" overstates where the research actually stands. A handful of in vitro papers and some immunomodulation research does not constitute a movement. Second, her framing of "I'm just going to leave that right there" on dosing is not responsible harm reduction. It is performative deniability. Viewers understand the implication.
Third, she raises a genuinely important scientific concern, whether the peptide reaches bacteria hiding in tissue, then drops it with "I don't know" and pivots to enthusiasm. That question is not a footnote. Borrelia's capacity for intracellular persistence and biofilm formation is one of the central unsolved problems in Lyme research, as outlined by Sapi et al. in 2012 in PLOS ONE. If LL37 cannot penetrate those compartments at therapeutic concentrations without causing local toxicity, the in vitro data is of limited clinical relevance.
She also called it a "two to four week course," citing no source. That framing implies an established protocol that does not exist in human trials.
What should you actually know?
LL37 is not approved by the FDA for any indication. It is not a proven Lyme disease treatment. Sourcing injectable peptides online carries serious risks that have nothing to do with whether the molecule is interesting in a lab.
Unregulated peptide suppliers vary wildly in purity, sterile preparation, and actual peptide content. A 2018 analysis published by Jochems et al. in the Journal of Pharmaceutical and Biomedical Analysis found significant discrepancies between labeled and actual peptide content in commercially sold research peptides. Injecting a contaminated or mislabeled compound in the context of a chronic illness is not biohacking. It is an uncontrolled risk layered on top of an already complicated condition.
For people living with chronic Lyme or post-treatment Lyme disease syndrome, the desperation the creator is tapping into is real and understandable. That is exactly why this kind of content carries more weight than it should. If LL37 eventually clears human trials for Lyme, that will be worth covering. It has not done that yet.